跳轉至內容
Merck
全部照片(1)

重要文件

Y0000009

Fluphenazine enantate

European Pharmacopoeia (EP) Reference Standard

同義詞:

2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C29H38F3N3O2S
CAS號碼:
分子量::
549.69
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

fluphenazine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

FC(F)(F)c1cc2c(cc1)Sc3c(cccc3)N2CCCN4CCN(CC4)CCOC(=O)CCCCCC

InChI

1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3

InChI 密鑰

LRWSFOSWNAQHHW-UHFFFAOYSA-N

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Fluphenazine enantate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 3 Oral - Repr. 1A

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

W M Glazer
The Journal of clinical psychiatry, 45(5 Pt 2), 28-35 (1984-05-01)
The risks and benefits associated with depot fluphenazine are reassessed by a review and critique of the literature, with an emphasis on controlled studies comparing depot to oral preparations. Specific gaps in our knowledge are noted and recommendations are made
A C Altamura et al.
Psychopharmacology, 87(1), 30-33 (1985-01-01)
Seven outpatients already receiving neuroleptic drugs by depot intramuscular injections were treated in two consecutive 3-week periods with 25 mg fluphenazine doses as enanthate and decanoate esters in a double-blind crossover study. They were assessed for incidence of akinesia, involuntary
K Yamada et al.
Pharmacology, 24(3), 147-155 (1982-01-01)
The cataleptic state induced by the depot-type preparations of fluphenazine (FZ) was investigated in mice. Intramuscular injections of FZ-enanthate or FZ-decanoate produced a marked and long-lasting catalepsy, which was antagonized by trihexyphenidyl, biperiden and promethazine but not by l-dopa. These
J P Lanza et al.
Comptes rendus des seances de la Societe de biologie et de ses filiales, 173(4), 797-806 (1979-01-01)
The effects of two neuroleptics (pipotiazine and fluphenazine) and five long-acting neuroleptics (pipotiazine undecylenate and palmitate, fluphenazine enanthate and decanoate, fluopentixol decanoate) are tested in the rat, during an observation period of 20 to 40 days following only one injection
T P Hogan et al.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 28(4), 277-281 (1983-06-01)
The authors examined drug prescribing patterns and incidence of side effects in schizophrenic patients who committed suicide as compared with a matched control group. The groups did not differ in type of drug prescribed, though patients in the suicide group

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務